Adapt AO outperforms conventional lens

Article

At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL.

At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL, according to Ann Haustermans, Belgium.

The multicentre, prospective, intra-individual, comparative study enrolled 69 patients requiring bilateral cataract surgery. One eye of each subject received the Adapt AO and the other the spherical Akreos Adapt lens. Follow-up data was collected at one and three months and one and two years, and patients completed a questionnaire assessing their quality of vision at three months.

At one-month follow-up, the Adapt AO performed significantly better in low contrast UCVA (p=0.03) and BCVA (p=0.047). It was also found to perform better than the spherical Adapt at all spatial frequencies in photopic contrast sensitivity and at 1, 5 and 6 cpd in mesopic contrast sensitivity. At three-months follow-up, the lenses performed equally but at one year the Adapt AO performed better in high contrast UCVA and BCVA.

Dr Haustermanns concluded that the aspheric Akreos Adapt AO lens offers better optical performance than the conventional spherical Adapt IOL.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.